Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Cml-Imatinib'

Cml-Imatinib published presentations and documents on DocSlides.

Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat
Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat
by hadly
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof C...
Overview of CML & Recent Advances
Overview of CML & Recent Advances
by stella
I. ntroduction. CML is a clonal myeloproliferative...
Imatinib Resistance Geoffrey L. Uy, M.D.
Imatinib Resistance Geoffrey L. Uy, M.D.
by karlyn-bohler
Associate Professor . of Medicine. Division of On...
Imatinib
Imatinib
by phoebe-click
Resistance. Geoffrey L. Uy, M.D.. Associate Prof...
Impact of Imatinib interruption & duration of prior Hyd
Impact of Imatinib interruption & duration of prior Hyd
by pamella-moone
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof ...
Modeling Imatinib-Treated Chronic Myeloid Leukemia
Modeling Imatinib-Treated Chronic Myeloid Leukemia
by phoebe-click
Cara Peters. cpeters3@math.umd.edu. Advisor: Dr. ...
Chronic M yeloid Leukemia
Chronic M yeloid Leukemia
by eliza
Amer Rassam, M.D.. Learning Objectives. Myeloproli...
Chronic
Chronic
by briana-ranney
M. yeloid Leukemia. Amer Rassam, M.D.. Learning O...
OHSU Updates in Hematology
OHSU Updates in Hematology
by calandra-battersby
and. Breast Cancer Conference. CML . ASH Update. ...
CML Group | Growing Accessibility | cmlgrp.com
CML Group | Growing Accessibility | cmlgrp.com
by isla
Building A Workplace Accessibility Ecosystem . Fun...
Chronic Myeloid Leukemia CML
Chronic Myeloid Leukemia CML
by eleanor
BSW00073 / OK 11 - ONC - 152 1 July , 2011 Fact Sh...
25/4/2017 CML : MOLECULAR PATHOLOGY AND CLINICAL MANIFESTATIONS
25/4/2017 CML : MOLECULAR PATHOLOGY AND CLINICAL MANIFESTATIONS
by ImNotABaby
Introduction and Basics. Clonal. hematopoietic st...
Treatment of Imatinib -resistant GIST
Treatment of Imatinib -resistant GIST
by beatrice
: . The Next Generation. Dr. Michael Heinrich, M....
SCIENTIFIC DISCUSSION 1 Introduction The scope of this Type II varia
SCIENTIFIC DISCUSSION 1 Introduction The scope of this Type II varia
by evelyn
Metastasis of DFSP is rare, occurring in approxima...
S1 TableRisk classification according to Armed Forces Institute of Pa
S1 TableRisk classification according to Armed Forces Institute of Pa
by finley
A FIP risk criteria 3 ears of imatinib (n= 31) 5 Y...
GREETING BUENOS DÍAS GOOD MORNING
GREETING BUENOS DÍAS GOOD MORNING
by escapistlego
BONJOUR. Tolerance of . Imatinib. . Dasatinib. ...
ADVANCES IN THERAPY FOR SARCOMA AND GIST
ADVANCES IN THERAPY FOR SARCOMA AND GIST
by ellena-manuel
Angela . Cioffi. , MD. Sarcoma Research Program c...
Gastrointestinal Stromal Tumors
Gastrointestinal Stromal Tumors
by tawny-fly
Definition of Gastrointestinal Stromal Tumor . th...
ETV1 is a lineage survival factor that cooperates with KIT
ETV1 is a lineage survival factor that cooperates with KIT
by test
stromal. tumors. Introduction. Tim Butler. March...
Myeloproliferative Neoplasms 2015
Myeloproliferative Neoplasms 2015
by jocelyn
Robert J. Jacobson MD, FACP , FRCP(C).. Florida Ca...
CML Commercial Real Estate Services, LLC
CML Commercial Real Estate Services, LLC
by cappi
Property . Overview. Fantastic corner location. Hi...
Epidemiology of Chronic Myeloid Leukemia
Epidemiology of Chronic Myeloid Leukemia
by scarlett
Tom Radivoyevitch, PhD. Assistant Professor . Epid...
Integrated quantitative modeling of
Integrated quantitative modeling of
by sylvia
radiation induced . chronic . myeloid leukemia (CM...
x0000x0000__________
x0000x0000__________
by megan
Original Article Chronic Myelogenous Leukemia in E...
Relapse in Chronic Myeloid
Relapse in Chronic Myeloid
by ella
A Guide for A relapse is the return of leukaemia ...
ChronicMyeloidLeukemiainChildhood
ChronicMyeloidLeukemiainChildhood
by williams
::5::ReviewArticleKeyWords:Chronicmyeloidleukemia,...
Dr. Maher jabbar salih
Dr. Maher jabbar salih
by Vikingwarrior
. Medical oncologist . Al-. basrah. . onco. . Cen...
MEMORANDUM
MEMORANDUM
by esther
1 All Interested Vendors From Part I Summary...
MEMORANDUM
MEMORANDUM
by teresa
1 All Interested Vendors From: Part I. Su...
#RESO16 MLS Best Practice –
#RESO16 MLS Best Practice –
by sandsomber
Data Management. Denee Evans, CEO CMLS. Ethan Ba...
IU OREChem
IU OREChem
by luanne-stotts
Summary Slides. Marlon Pierce, Geoffrey Fox, . S...
MONASSEetal.:THREE-STEPIMAGERECTIFICATION1
MONASSEetal.:THREE-STEPIMAGERECTIFICATION1
by pasty-toler
Three-stepimagerecticationPascalMONASSE1monasse@i...
Capital Market Literacy
Capital Market Literacy
by jane-oiler
MASTER PLAN (CML-MP). Interim Report. 1. Outline....
Proceedings of UCLA HealthVOLUME 22201CLINICAL VIGNETTE
Proceedings of UCLA HealthVOLUME 22201CLINICAL VIGNETTE
by tracy
Dermatofibrosarcoma protuberans Fukai Leo Chuang, ...
La LAL del adulto tiene mal pronóstico
La LAL del adulto tiene mal pronóstico
by walsh
PETHEMA LAL infantil. PETHEMA LAL Adulto. 15%. 25%...
Jon Trent, MD, PhD Professor of Medicine
Jon Trent, MD, PhD Professor of Medicine
by jane-oiler
Sarcoma . Medical Oncology. The University of . M...
Prof Giovanni Brandi
Prof Giovanni Brandi
by liane-varnes
. University. of Bologna . Advances. in . c...
Clinical Considerations in
Clinical Considerations in
by faustina-dinatale
Evidence-based Management . of GIST. Program Goal...
Anticancer Therapy:
Anticancer Therapy:
by stefany-barnette
Kinase. Inhibitors. Charles Harrell. Outline of ...
Philadephia
Philadephia
by danika-pritchard
chromosomal positive acute lymphoblastic leukemi...